Biogen and Alkermes Report Results of Diroximel Fumarate in P-III EVOLVE-MS-2 Study for Multiple Sclerosis
Shots:
- The P-III EVOLVE-MS-2 study assessing the GI tolerability of Diroximel Fumarate (462mg- bid) vs Tecfidera (dimethyl fumarate- 240 mg- bid) in 506 patients with RRMS
- The P-III EVOLVE-MS-2 study results demonstrated superiority in gastrointestinal (GI) tolerability with a symptom intensity score ≥2 on the IGISIS rating scale and low discontinuation rates of <1% due to GI adverse events
- Diroximel fumarate is a fumarate therapy designed to convert to monomethyl fumarate in the body and is under the US FDA review with its expected PDUFA date in Q4’19. Post-FDA’s approval- Biogen plans to market diroximel fumarate under the name Vumerity
Click here to read full press release/ article
| Ref: Biogen | Image: Biogen
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com